Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,825
  • Shares Outstanding, K 15,362
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,000 K
  • 60-Month Beta 3.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.26
  • Number of Estimates 1
  • High Estimate -0.26
  • Low Estimate -0.26
  • Prior Year -0.75
  • Growth Rate Est. (year over year) +65.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.72 +124.42%
on 07/07/20
4.98 -22.49%
on 08/04/20
+2.15 (+125.73%)
since 07/06/20
3-Month
0.81 +376.54%
on 05/07/20
4.98 -22.49%
on 08/04/20
+3.03 (+366.41%)
since 05/06/20
52-Week
0.62 +527.34%
on 04/02/20
6.58 -41.34%
on 08/07/19
-2.61 (-40.34%)
since 08/06/19

Most Recent Stories

More News
Why Developments for Targeted Therapies Are Expected to Drive Sales for Brain Tumor Drug Market

, /PRNewswire/ -- The global brain tumor drugs market was valued at about in 2018 and is expected to grow to at a CAGR of 9.2% through 2022. The brain tumor drugs market consist of sales of drugs which...

CNSP : 1.8700 (-3.11%)
VBIV : 4.21 (-6.55%)
PDSB : 3.86 (-11.26%)
CRDF : 5.69 (-2.90%)
CLVS : 6.23 (-3.63%)
BMY : 61.33 (+2.75%)
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?

PDS Biotechnology (PDSB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PDSB : 3.86 (-11.26%)
PDS Biotechnology Corp. Announces Clinical Collaboration with Merck

PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of multi-functional immunotherapeutic products, today announced a...

MRK : 81.05 (-0.72%)
PDSB : 3.86 (-11.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade PDSB with:

Business Summary

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary...

See More

Key Turning Points

2nd Resistance Point 4.57
1st Resistance Point 4.22
Last Price 3.86
1st Support Level 3.68
2nd Support Level 3.49

See More

52-Week High 6.58
Fibonacci 61.8% 4.30
Last Price 3.86
Fibonacci 50% 3.60
Fibonacci 38.2% 2.89
52-Week Low 0.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar